UniProt ID | NEMO_HUMAN | |
---|---|---|
UniProt AC | Q9Y6K9 | |
Protein Name | NF-kappa-B essential modulator | |
Gene Name | IKBKG | |
Organism | Homo sapiens (Human). | |
Sequence Length | 419 | |
Subcellular Localization | Cytoplasm . Nucleus . Sumoylated NEMO accumulates in the nucleus in response to genotoxic stress. | |
Protein Description | Regulatory subunit of the IKK core complex which phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor. Its binding to scaffolding polyubiquitin seems to play a role in IKK activation by multiple signaling receptor pathways. However, the specific type of polyubiquitin recognized upon cell stimulation (either 'Lys-63'-linked or linear polyubiquitin) and its functional importance is reported conflictingly. Also considered to be a mediator for TAX activation of NF-kappa-B. Could be implicated in NF-kappa-B-mediated protection from cytokine toxicity. Essential for viral activation of IRF3. Involved in TLR3- and IFIH1-mediated antiviral innate response; this function requires 'Lys-27'-linked polyubiquitination.. | |
Protein Sequence | MNRHLWKSQLCEMVQPSGGPAADQDVLGEESPLGKPAMLHLPSEQGAPETLQRCLEENQELRDAIRQSNQILRERCEELLHFQASQREEKEFLMCKFQEARKLVERLGLEKLDLKRQKEQALREVEHLKRCQQQMAEDKASVKAQVTSLLGELQESQSRLEAATKECQALEGRARAASEQARQLESEREALQQQHSVQVDQLRMQGQSVEAALRMERQAASEEKRKLAQLQVAYHQLFQEYDNHIKSSVVGSERKRGMQLEDLKQQLQQAEEALVAKQEVIDKLKEEAEQHKIVMETVPVLKAQADIYKADFQAERQAREKLAEKKELLQEQLEQLQREYSKLKASCQESARIEDMRKRHVEVSQAPLPPAPAYLSSPLALPSQRRSPPEEPPDFCCPKCQYQAPDMDTLQIHVMECIE | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
8 | Phosphorylation | MNRHLWKSQLCEMVQ CCCCHHHHHHHHHHC | 19.46 | - | |
17 | Phosphorylation | LCEMVQPSGGPAADQ HHHHHCCCCCCCCCC | 39.01 | - | |
31 | Phosphorylation | QDVLGEESPLGKPAM CCCCCCCCCCCCCCH | 22.56 | 12657630 | |
43 | Phosphorylation | PAMLHLPSEQGAPET CCHHCCCCCCCCHHH | 49.24 | 12657630 | |
50 | Phosphorylation | SEQGAPETLQRCLEE CCCCCHHHHHHHHHH | 27.42 | 23312004 | |
68 | Phosphorylation | LRDAIRQSNQILRER HHHHHHHHHHHHHHH | 22.36 | 17977820 | |
85 | Phosphorylation | ELLHFQASQREEKEF HHHCHHHCHHHHHHH | 20.98 | 17977820 | |
96 | Acetylation | EKEFLMCKFQEARKL HHHHHHHHHHHHHHH | 35.80 | 25953088 | |
111 | Ubiquitination | VERLGLEKLDLKRQK HHHHCHHHHHHHHHH | 52.95 | 21906983 | |
111 | Phosphorylation | VERLGLEKLDLKRQK HHHHCHHHHHHHHHH | 52.95 | 27251275 | |
115 | Ubiquitination | GLEKLDLKRQKEQAL CHHHHHHHHHHHHHH | 53.07 | PubMed | |
118 | Ubiquitination | KLDLKRQKEQALREV HHHHHHHHHHHHHHH | 56.69 | - | |
139 | Ubiquitination | QQQMAEDKASVKAQV HHHHHHCHHHHHHHH | 33.78 | 21906983 | |
143 | Ubiquitination | AEDKASVKAQVTSLL HHCHHHHHHHHHHHH | 30.52 | 21906983 | |
147 | Phosphorylation | ASVKAQVTSLLGELQ HHHHHHHHHHHHHHH | 11.11 | 27050516 | |
148 | Phosphorylation | SVKAQVTSLLGELQE HHHHHHHHHHHHHHH | 23.81 | 27050516 | |
165 | Ubiquitination | SRLEAATKECQALEG HHHHHHHHHHHHHHH | 52.33 | - | |
178 | Phosphorylation | EGRARAASEQARQLE HHHHHHHHHHHHHHH | 29.29 | 23663014 | |
179 (in isoform 2) | Ubiquitination | - | 43.46 | - | |
186 | Phosphorylation | EQARQLESEREALQQ HHHHHHHHHHHHHHH | 51.01 | 23663014 | |
196 | Phosphorylation | EALQQQHSVQVDQLR HHHHHHHCHHHHHHH | 15.20 | 30108239 | |
208 | Phosphorylation | QLRMQGQSVEAALRM HHHHHCCHHHHHHHH | 28.84 | 28555341 | |
216 | Phosphorylation | VEAALRMERQAASEE HHHHHHHHHHHCCHH | 34.90 | 27251275 | |
224 | Ubiquitination | RQAASEEKRKLAQLQ HHHCCHHHHHHHHHH | 51.27 | PubMed | |
226 | Ubiquitination | AASEEKRKLAQLQVA HCCHHHHHHHHHHHH | 60.28 | 21906983 | |
233 (in isoform 2) | Ubiquitination | - | 5.32 | - | |
246 | Ubiquitination | QEYDNHIKSSVVGSE HHHHHHHCHHHHCCH | 29.18 | 21906983 | |
252 | Phosphorylation | IKSSVVGSERKRGMQ HCHHHHCCHHHCCCC | 23.71 | 28857561 | |
255 | Acetylation | SVVGSERKRGMQLED HHHCCHHHCCCCHHH | 49.61 | 30589477 | |
255 | Ubiquitination | SVVGSERKRGMQLED HHHCCHHHCCCCHHH | 49.61 | - | |
264 | Ubiquitination | GMQLEDLKQQLQQAE CCCHHHHHHHHHHHH | 48.60 | 21906983 | |
264 | Phosphorylation | GMQLEDLKQQLQQAE CCCHHHHHHHHHHHH | 48.60 | 27251275 | |
277 | Sumoylation | AEEALVAKQEVIDKL HHHHHHHHHHHHHHH | 39.24 | - | |
277 | Sumoylation | AEEALVAKQEVIDKL HHHHHHHHHHHHHHH | 39.24 | 14651848 | |
277 | Ubiquitination | AEEALVAKQEVIDKL HHHHHHHHHHHHHHH | 39.24 | 14651848 | |
283 | Ubiquitination | AKQEVIDKLKEEAEQ HHHHHHHHHHHHHHH | 50.78 | 21906983 | |
285 | Ubiquitination | QEVIDKLKEEAEQHK HHHHHHHHHHHHHHC | 60.28 | 15620648 | |
292 | Ubiquitination | KEEAEQHKIVMETVP HHHHHHHCCHHHHHH | 36.37 | 21906983 | |
297 | Phosphorylation | QHKIVMETVPVLKAQ HHCCHHHHHHHHHHH | 16.41 | 20068231 | |
300 | Ubiquitination | IVMETVPVLKAQADI CHHHHHHHHHHHHHH | 8.12 | 17363905 | |
302 | Phosphorylation | METVPVLKAQADIYK HHHHHHHHHHHHHHH | 38.39 | 27642862 | |
302 | Ubiquitination | METVPVLKAQADIYK HHHHHHHHHHHHHHH | 38.39 | 21906983 | |
308 | Phosphorylation | LKAQADIYKADFQAE HHHHHHHHHHHHHHH | 10.73 | 29083192 | |
309 | Ubiquitination | KAQADIYKADFQAER HHHHHHHHHHHHHHH | 41.64 | 21890473 | |
309 | Ubiquitination | KAQADIYKADFQAER HHHHHHHHHHHHHHH | 41.64 | 14651848 | |
309 | Sumoylation | KAQADIYKADFQAER HHHHHHHHHHHHHHH | 41.64 | 14651848 | |
309 | Phosphorylation | KAQADIYKADFQAER HHHHHHHHHHHHHHH | 41.64 | 27642862 | |
309 | Sumoylation | KAQADIYKADFQAER HHHHHHHHHHHHHHH | 41.64 | - | |
320 | Phosphorylation | QAERQAREKLAEKKE HHHHHHHHHHHHHHH | 56.27 | 27251275 | |
321 | Ubiquitination | AERQAREKLAEKKEL HHHHHHHHHHHHHHH | 47.66 | 20010814 | |
323 (in isoform 2) | Ubiquitination | - | 37.32 | - | |
325 | Ubiquitination | AREKLAEKKELLQEQ HHHHHHHHHHHHHHH | 46.04 | 17728323 | |
326 | Ubiquitination | REKLAEKKELLQEQL HHHHHHHHHHHHHHH | 45.13 | 17728323 | |
342 | Ubiquitination | QLQREYSKLKASCQE HHHHHHHHHHHHHHH | 53.78 | - | |
344 | Ubiquitination | QREYSKLKASCQESA HHHHHHHHHHHHHHH | 41.83 | 21906983 | |
353 (in isoform 2) | Ubiquitination | - | 5.42 | - | |
358 | Ubiquitination | ARIEDMRKRHVEVSQ HHHHHHHHHHCCHHC | 39.97 | - | |
364 | Phosphorylation | RKRHVEVSQAPLPPA HHHHCCHHCCCCCCC | 13.71 | 26074081 | |
374 | Phosphorylation | PLPPAPAYLSSPLAL CCCCCCCCCCCCCCC | 13.17 | 25159151 | |
376 | Phosphorylation | PPAPAYLSSPLALPS CCCCCCCCCCCCCCC | 19.75 | 23401153 | |
377 | Phosphorylation | PAPAYLSSPLALPSQ CCCCCCCCCCCCCCC | 22.72 | 25159151 | |
377 (in isoform 2) | Ubiquitination | - | 22.72 | - | |
377 | Ubiquitination | PAPAYLSSPLALPSQ CCCCCCCCCCCCCCC | 22.72 | 21890473 | |
383 | Phosphorylation | SSPLALPSQRRSPPE CCCCCCCCCCCCCCC | 36.85 | 27794612 | |
387 | Phosphorylation | ALPSQRRSPPEEPPD CCCCCCCCCCCCCCC | 47.17 | 29255136 | |
399 | Ubiquitination | PPDFCCPKCQYQAPD CCCCCCCCCCCCCCC | 21.76 | 14695475 | |
442 | Phosphorylation | ------------------------------ ------------------------------ | 27642862 | ||
445 | Phosphorylation | --------------------------------- --------------------------------- | 27642862 | ||
455 | Phosphorylation | ------------------------------------------- ------------------------------------------- | 24719451 | ||
467 | Ubiquitination | ------------------------------------------------------- ------------------------------------------------------- | 17363905 |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
8 | S | Phosphorylation | Kinase | GSK3B | P49841 | PSP |
17 | S | Phosphorylation | Kinase | GSK3B | P49841 | PSP |
31 | S | Phosphorylation | Kinase | GSK3B | P49841 | PSP |
31 | S | Phosphorylation | Kinase | IKBKB | O14920 | GPS |
43 | S | Phosphorylation | Kinase | DNAPK | P78527 | PSP |
43 | S | Phosphorylation | Kinase | GSK3B | P49841 | PSP |
43 | S | Phosphorylation | Kinase | IKBKB | O14920 | GPS |
68 | S | Phosphorylation | Kinase | IKBKB | O14920 | GPS |
85 | S | Phosphorylation | Kinase | ATM | Q62388 | PSP |
85 | S | Phosphorylation | Kinase | PRKCA | P17252 | GPS |
85 | S | Phosphorylation | Kinase | IKBKB | O14920 | GPS |
85 | S | Phosphorylation | Kinase | ATM | Q13315 | Uniprot |
141 | S | Phosphorylation | Kinase | PRKCA | P17252 | GPS |
374 | Y | Phosphorylation | Kinase | FYN | P06241 | PSP |
374 | Y | Phosphorylation | Kinase | FGR | P09769 | PSP |
374 | Y | Phosphorylation | Kinase | LYN | P07948 | PSP |
374 | Y | Phosphorylation | Kinase | SRC | P12931 | PSP |
376 | S | Phosphorylation | Kinase | IKBKB | O14920 | GPS |
- | K | Ubiquitination | E3 ubiquitin ligase | RBCK1 | Q9BYM8 | PMID:19675569 |
- | K | Ubiquitination | E3 ubiquitin ligase | PRKN | O60260 | PMID:19880420 |
- | K | Ubiquitination | E3 ubiquitin ligase | RNF31 | Q96EP0 | PMID:24469399 |
- | K | Ubiquitination | E3 ubiquitin ligase | TRAF6 | Q9Y4K3 | PMID:15125833 |
- | K | Ubiquitination | E3 ubiquitin ligase | BIRC2 | Q13490 | PMID:12867425 |
- | K | Ubiquitination | E3 ubiquitin ligase | MALT1 | Q9UDY8 | PMID:14695475 |
- | K | Ubiquitination | E3 ubiquitin ligase | MIB2 | Q96AX9 | PMID:21896478 |
- | K | Ubiquitination | E3 ubiquitin ligase | TRIM23 | P36406 | PMID:32296023 |
- | K | Ubiquitination | E3 ubiquitin ligase | ipaH9.8 | Q8VSC3 | PMID:32296023 |
Modified Location | Modified Residue | Modification | Function | Reference |
---|---|---|---|---|
27 | K | ubiquitylation |
| 14651848 |
63 | K | ubiquitylation |
| 14695475 |
63 | K | ubiquitylation |
| 14695475 |
68 | S | Phosphorylation |
| 17977820 |
85 | S | ubiquitylation |
| 16497931 |
85 | S | Sumoylation |
| 16497931 |
85 | S | Phosphorylation |
| 16497931 |
111 | K | ubiquitylation |
| 21455181 |
143 | K | ubiquitylation |
| 21455181 |
226 | K | ubiquitylation |
| 21455181 |
246 | K | ubiquitylation |
| 21455181 |
264 | K | ubiquitylation |
| 21455181 |
277 | K | ubiquitylation |
| 14651848 |
277 | K | Phosphorylation |
| 14651848 |
277 | K | Sumoylation |
| 14651848 |
277 | K | ubiquitylation |
| 14651848 |
277 | K | ubiquitylation |
| 14651848 |
285 | K | ubiquitylation |
| 15620648 |
285 | K | ubiquitylation |
| 15620648 |
292 | K | ubiquitylation |
| 21455181 |
302 | K | ubiquitylation |
| 21455181 |
309 | K | Sumoylation |
| 14651848 |
309 | K | ubiquitylation |
| 14651848 |
309 | K | ubiquitylation |
| 14651848 |
309 | K | ubiquitylation |
| 14651848 |
309 | K | ubiquitylation |
| 14651848 |
309 | K | Phosphorylation |
| 14651848 |
321 | K | ubiquitylation |
| 20010814 |
326 | K | ubiquitylation |
| 21455181 |
399 | K | ubiquitylation |
| 15620648 |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of NEMO_HUMAN !! |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
300291 | Ectodermal dysplasia, anhidrotic, with immunodeficiency X-linked (EDAID) | |||||
300301 | Ectodermal dysplasia, anhidrotic, with immunodeficiency, osteopetrosis and lymphedema (OLEDAID) | |||||
300584 | Immunodeficiency, NEMO-related, without anhidrotic ectodermal dysplasia (NEMOID) | |||||
300636 | Immunodeficiency 33 (IMD33) | |||||
300640 | Recurrent isolated invasive pneumococcal disease 2 (IPD2) | |||||
308300 | Incontinentia pigmenti (IP) | |||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Phosphorylation | |
Reference | PubMed |
"Large-scale proteomics analysis of the human kinome."; Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,Mann M., Daub H.; Mol. Cell. Proteomics 8:1751-1764(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-374 AND SER-387, ANDMASS SPECTROMETRY. | |
"A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377 AND SER-387, ANDMASS SPECTROMETRY. | |
"Phosphorylation of serine 68 in the IkappaB kinase (IKK)-bindingdomain of NEMO interferes with the structure of the IKK complex andtumor necrosis factor-alpha-induced NF-kappaB activity."; Palkowitsch L., Leidner J., Ghosh S., Marienfeld R.B.; J. Biol. Chem. 283:76-86(2008). Cited for: INTERACTION WITH IKBKB, PHOSPHORYLATION AT SER-68, AND MUTAGENESIS OFSER-68. | |
"Molecular linkage between the kinase ATM and NF-kappaB signaling inresponse to genotoxic stimuli."; Wu Z.H., Shi Y., Tibbetts R.S., Miyamoto S.; Science 311:1141-1146(2006). Cited for: INTERACTION WITH ATM, PHOSPHORYLATION AT SER-85, AND MUTAGENESIS OFSER-85. | |
"In vivo identification of inducible phosphoacceptors in theIKKgamma/NEMO subunit of human IkappaB kinase."; Carter R.S., Pennington K.N., Ungurait B.J., Ballard D.W.; J. Biol. Chem. 278:19642-19648(2003). Cited for: PHOSPHORYLATION AT SER-31; SER-43 AND SER-376. | |
Sumoylation | |
Reference | PubMed |
"SHARPIN forms a linear ubiquitin ligase complex regulating NF-kappaBactivity and apoptosis."; Ikeda F., Deribe Y.L., Skanland S.S., Stieglitz B., Grabbe C.,Franz-Wachtel M., van Wijk S.J., Goswami P., Nagy V., Terzic J.,Tokunaga F., Androulidaki A., Nakagawa T., Pasparakis M., Iwai K.,Sundberg J.P., Schaefer L., Rittinger K., Macek B., Dikic I.; Nature 471:637-641(2011). Cited for: UBIQUITINATION AT LYS-277; LYS-285; LYS-309; LYS-326; LYS-111;LYS-143; LYS-226; LYS-246; LYS-264; LYS-292 AND LYS-302 BY THE LUBACCOMPLEX, AND UBIQUITINATION AT LYS-139 AND LYS-283. | |
"A bacterial E3 ubiquitin ligase IpaH9.8 targets NEMO/IKKgamma todampen the host NF-kappaB-mediated inflammatory response."; Ashida H., Kim M., Schmidt-Supprian M., Ma A., Ogawa M., Sasakawa C.; Nat. Cell Biol. 12:66-73(2010). Cited for: INTERACTION WITH SHIGELLA FLEXNERI IPAH9.8, AND UBIQUITINATION ATLYS-309 AND LYS-321. | |
"Involvement of linear polyubiquitylation of NEMO in NF-kappaBactivation."; Tokunaga F., Sakata S., Saeki Y., Satomi Y., Kirisako T., Kamei K.,Nakagawa T., Kato M., Murata S., Yamaoka S., Yamamoto M., Akira S.,Takao T., Tanaka K., Iwai K.; Nat. Cell Biol. 11:123-132(2009). Cited for: UBIQUITINATION AT LYS-285 AND LYS-309. | |
"Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitinmediates NF-kappaB activation by genotoxic stress."; Huang T.T., Wuerzberger-Davis S.M., Wu Z.H., Miyamoto S.; Cell 115:565-576(2003). Cited for: SUMOYLATION AT LYS-277 AND LYS-309, UBIQUITINATION AT LYS-277 ANDLYS-309, MUTAGENESIS OF LYS-277 AND LYS-309, SUBCELLULAR LOCATION, ANDCHARACTERIZATION OF VARIANT EDAID ARG-417. | |
Ubiquitylation | |
Reference | PubMed |
"SHARPIN forms a linear ubiquitin ligase complex regulating NF-kappaBactivity and apoptosis."; Ikeda F., Deribe Y.L., Skanland S.S., Stieglitz B., Grabbe C.,Franz-Wachtel M., van Wijk S.J., Goswami P., Nagy V., Terzic J.,Tokunaga F., Androulidaki A., Nakagawa T., Pasparakis M., Iwai K.,Sundberg J.P., Schaefer L., Rittinger K., Macek B., Dikic I.; Nature 471:637-641(2011). Cited for: UBIQUITINATION AT LYS-277; LYS-285; LYS-309; LYS-326; LYS-111;LYS-143; LYS-226; LYS-246; LYS-264; LYS-292 AND LYS-302 BY THE LUBACCOMPLEX, AND UBIQUITINATION AT LYS-139 AND LYS-283. | |
"A bacterial E3 ubiquitin ligase IpaH9.8 targets NEMO/IKKgamma todampen the host NF-kappaB-mediated inflammatory response."; Ashida H., Kim M., Schmidt-Supprian M., Ma A., Ogawa M., Sasakawa C.; Nat. Cell Biol. 12:66-73(2010). Cited for: INTERACTION WITH SHIGELLA FLEXNERI IPAH9.8, AND UBIQUITINATION ATLYS-309 AND LYS-321. | |
"Involvement of linear polyubiquitylation of NEMO in NF-kappaBactivation."; Tokunaga F., Sakata S., Saeki Y., Satomi Y., Kirisako T., Kamei K.,Nakagawa T., Kato M., Murata S., Yamaoka S., Yamamoto M., Akira S.,Takao T., Tanaka K., Iwai K.; Nat. Cell Biol. 11:123-132(2009). Cited for: UBIQUITINATION AT LYS-285 AND LYS-309. | |
"Bcl10 activates the NF-kappaB pathway through ubiquitination ofNEMO."; Zhou H., Wertz I., O'Rourke K., Ultsch M., Seshagiri S., Eby M.,Xiao W., Dixit V.M.; Nature 427:167-171(2004). Cited for: FUNCTION, UBIQUITINATION AT LYS-399, AND MUTAGENESIS OF LYS-399. | |
"The Crohn's disease protein, NOD2, requires RIP2 in order to induceubiquitinylation of a novel site on NEMO."; Abbott D.W., Wilkins A., Asara J.M., Cantley L.C.; Curr. Biol. 14:2217-2227(2004). Cited for: UBIQUITINATION AT LYS-285, AND MUTAGENESIS OF LYS-115; LYS-224;LYS-285 AND LYS-399. |